^
No biomarker
Multiple Myeloma
ALLO-715
Sensitive
:
B
Allogene Therapeutics Press Release - 2wk
CD20 underexpression
Multiple Myeloma
lenalidomide
Resistant
:
D
Onco Targets Ther - 2wk
CD20 underexpression
Multiple Myeloma
elotuzumab
Resistant
:
D
Onco Targets Ther - 2wk
GPRC5D overexpression
Multiple Myeloma
JNJ-64407564
Sensitive
:
D
Blood Adv - 2wk
No biomarker
Multiple Myeloma
isatuximab-irfc
Sensitive
:
A1
Sanofi Press Release - 3wk
PPP1R15B overexpression
Multiple Myeloma
salubrinal
Sensitive
:
D
CSI-FCS 2020 - 3wk
No biomarker
Multiple Myeloma
pomalidomide + elotuzumab
Sensitive
:
A1
No biomarker
Multiple Myeloma
carfilzomib
Sensitive
:
A1
No biomarker
Multiple Myeloma
bortezomib + panobinostat
Sensitive
:
A1
No biomarker
Multiple Myeloma
bortezomib + pegylated liposomal doxorubicin
Sensitive
:
A1
No biomarker
Multiple Myeloma
bortezomib
Sensitive
:
A1
No biomarker
Multiple Myeloma
SVd
Sensitive
:
A1
No biomarker
Multiple Myeloma
pomalidomide
Sensitive
:
A1
No biomarker
Multiple Myeloma
thalidomide
Sensitive
:
A1
No biomarker
Multiple Myeloma
isatuximab-irfc
Sensitive
:
A1
No biomarker
Multiple Myeloma
prednisone + thalidomide + melphalan
Sensitive
:
A1
No biomarker
Multiple Myeloma
lenalidomide + daratumumab/hyaluronidase
Sensitive
:
A1
No biomarker
Multiple Myeloma
lenalidomide + elotuzumab
Sensitive
:
A1
No biomarker
Multiple Myeloma
lenalidomide + daratumumab
Sensitive
:
A1
No biomarker
Multiple Myeloma
selinexor
Sensitive
:
A1
No biomarker
Multiple Myeloma
lenalidomide + ixazomib
Sensitive
:
A1
No biomarker
Multiple Myeloma
daratumumab/hyaluronidase
Sensitive
:
A1
No biomarker
Multiple Myeloma
bortezomib
Sensitive
:
A1
No biomarker
Multiple Myeloma
lenalidomide
Sensitive
:
A1
No biomarker
Multiple Myeloma
VTD
Sensitive
:
A1
No biomarker
Multiple Myeloma
belantamab mafodotin
Sensitive
:
A1
No biomarker
Multiple Myeloma
denosumab
Sensitive
:
A1
No biomarker
Multiple Myeloma
melphalan flufenamide
Sensitive
:
A1
No biomarker
Multiple Myeloma
pomalidomide + isatuximab-irfc
Sensitive
:
A1
No biomarker
Multiple Myeloma
lenalidomide + carfilzomib
Sensitive
:
A1
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our